{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:36Z","timestamp":1766514156473,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,1,26]]},"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:p>A 50-year-old woman with a history of Crohn\u2019s disease treated with adalimumab presented with left hand pain and duskiness. Angiogram showed non-filling of the radial and digital arteries of the hand. Antiphospholipid antibody testing was positive, leading to a diagnosis of antitumour necrosis factor-induced antiphospholipid syndrome. Adalimumab was discontinued, and she was treated with the vitamin K antagonist warfarin and low-dose aspirin. Upon resolution of the antiphospholipid antibodies, she was transitioned to aspirin alone without recurrence of thrombosis.<\/jats:p>","DOI":"10.1136\/bcr-2019-232907","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T04:39:23Z","timestamp":1581309563000},"page":"e232907","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome"],"prefix":"10.1136","volume":"13","author":[{"given":"Shashank","family":"Cheemalavagu","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Michigan Hospital, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara S","family":"McCoy","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason S","family":"Knight","sequence":"additional","affiliation":[{"name":"Internal Medicine-Rheumatology, University of Michigan Hospital, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,2,9]]},"reference":[{"key":"2025082712455971000_13.2.e232907.1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000450877","article-title":"Infliximab-Induced lupus: a case report","volume":"24","author":"Magno Pereira","year":"2017","journal-title":"GE Port J Gastroenterol"},{"key":"2025082712455971000_13.2.e232907.2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/03009740902832753","article-title":"Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis","volume":"39","author":"Vereckei","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"2025082712455971000_13.2.e232907.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.008"},{"key":"2025082712455971000_13.2.e232907.4","first-page":"546","article-title":"Arterial thrombosis with anti-phospholipid antibodies induced by infliximab","volume":"17","author":"Nosbaum","year":"2007","journal-title":"Eur J Dermatol"},{"key":"2025082712455971000_13.2.e232907.5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s10067-013-2244-0","article-title":"Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature","volume":"32","author":"Hemmati","year":"2013","journal-title":"Clin Rheumatol"},{"key":"2025082712455971000_13.2.e232907.6","first-page":"355","article-title":"Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006","volume":"19","author":"Petitpain","year":"2009","journal-title":"Biomed Mater Eng"},{"key":"2025082712455971000_13.2.e232907.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.30209"},{"key":"2025082712455971000_13.2.e232907.8","article-title":"Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome","volume":"2014","author":"Virupannavar","year":"2014","journal-title":"Case Rep Rheumatol"},{"key":"2025082712455971000_13.2.e232907.9","doi-asserted-by":"publisher","DOI":"10.1186\/ar1173"},{"key":"2025082712455971000_13.2.e232907.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018093"},{"key":"2025082712455971000_13.2.e232907.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2025082712455971000_13.2.e232907.12","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395803"},{"key":"2025082712455971000_13.2.e232907.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1314-8"},{"key":"2025082712455971000_13.2.e232907.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2007.02.007"},{"key":"2025082712455971000_13.2.e232907.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.485"},{"key":"2025082712455971000_13.2.e232907.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01609","article-title":"Environmental triggers of autoreactive responses: induction of antiphospholipid antibody formation","volume":"10","author":"Martirosyan","year":"2019","journal-title":"Front Immunol"},{"key":"2025082712455971000_13.2.e232907.17","doi-asserted-by":"publisher","DOI":"10.1080\/10409230903193307"},{"key":"2025082712455971000_13.2.e232907.18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12026-013-8407-x","article-title":"Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative","volume":"56","author":"Coloma Baz\u00e1n","year":"2013","journal-title":"Immunol Res"},{"key":"2025082712455971000_13.2.e232907.19","doi-asserted-by":"publisher","DOI":"10.1157\/13115821"},{"key":"2025082712455971000_13.2.e232907.20","doi-asserted-by":"crossref","unstructured":"Baquero-Salamanca M , T\u00e9llez-Ar\u00e9valo AM , Calderon-Ospina C . Variability in the International normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher? BMJ Case Rep 2015;2015. doi:doi:10.1136\/bcr-2014-209013. [Epub ahead of print: 09 Apr 2015].","DOI":"10.1136\/bcr-2014-209013"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:46:11Z","timestamp":1756323971000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,9]]},"published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1136\/bcr-2019-232907"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232907","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}